UNAUDITED (STANDALONE) FINANCIAL RESULTS The Board of Director have considered and approved the Unaudited (Standalone) Financial Results along with Limited Review Report thereon for the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Johnson Pharmacare Limited reported nil revenue from operations for the third quarter (Q3 FY26) as well as for the nine months ended 31 December 2025, indicating the company remains non-operational. The company posted a loss after tax of Rs 6.40 lakhs in Q3 FY26, wider than the Rs 2.99 lakh loss in Q3 FY25, taking the nine-month loss to Rs 12.34 lakhs versus Rs 7.06 lakhs in the same period last year. A notable change this year is the emergence of finance costs of Rs 4.28 lakhs for nine months FY26 against nil in the prior year period. The statutory auditor VRSK & Associates issued a limited review report with a reference to an 'Emphasis of Matter'. The audited full-year FY25 column also shows an exceptional item of Rs 17.16 lakhs and a full-year loss of Rs 58.38 lakhs.
With zero operational revenue, widening losses and a fresh Emphasis of Matter from auditors, shareholders should view this as a red flag on the company's business continuity and earnings quality; near-term stock sentiment is likely negative until operations or a clear revival plan emerges.